共 50 条
- [43] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
- [48] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) Investigational New Drugs, 2018, 36 : 919 - 926